Belgium Canada Singapore United States of America

Rond-Point R.Schuman 11 Suite 300, 1090 Homer St 146 Robinson Road #07-01 712 H Street NE, Suite 1110
1040 Brussels Vancouver, BC V6B 2W9 Singapore 068909 Washington DC 20002
Phone: +32 2 588 5803 Phone: +1 778 807 9713 Phone: +65 65009377 Phone: +1 202 869 0988
Fax: +32 2 588 5804 Fax: +1 778 807 9657 Fax: +65 68355173 Fax: +1 202 869 1121

PRESS RELEASE

Date: 13th October 2016

Title: Mr Raymond Dabney, CEO of CBIS, accepts invitation to speak at Harvard Medical School

IRVINE, CA (Marketwired September 26, 2016) Cannabis Science, Inc. (OTC PINK: CBIS), a U.S.
company specializing in the development of cannabis-based medicines, announces that its President,
Chief Executive Officer, and Co-Founder, Mr. Raymond C. Dabney, has accepted an invitation to speak
at Harvard Medical School this November. Mr. Dabney will address speak at the Dana Farber/Harvard
Cancer Center (DF/HCC), one of the largest cancer research centers in the world with more than 1,100
cancer researchers and over $600 million in cancer research funding. He will discuss CBIS drug
development initiatives targeting a variety of cancers, within the context of a number of other disorders,
such as autism spectrum disorders, asthma, as well as pain management.

I am excited to have the opportunity to tell the CBIS story to a new audience at the Harvard Medical
School. In discussing our work with the experts and thought-leaders at Harvard as well as by learning
more about the cutting-edge research being done at DF/HCC we will be better positioned to continue
our drug development program on effective treatments that will help the largest possible number of
people in need, said Mr. Dabney.
Mr. Dabney also agreed to participate in the Harvard Medical Schools Global Health Catalyst Summit in
April 2017, and to serve as a Role Model Speaker to minorities and K-12 students beginning in early
2017. For the Global Health Catalyst Summit, Mr. Dabney will be one of the lead Diaspora keynote
speakers and he will explore the use of cannabinoids in the management of acute and chronic diseases
within the African Diaspora. Chronic diseases like cancer and heart diseases represent an ever growing
burden of disease across Africa. Mr. Dabney has been a role model for many years and he will share with
K-12 students, will motivate young leaders to develop integrated, sustainable and successful business
enterprises. I look forward to participating in these three, exciting programs at the Harvard Medical
School over the next several months. Not only will I have the opportunity to share ideas with recognized
experts and help inspire young leaders, but I will also have the opportunity to create visibility for the CBIS
brand in a manner that will be mutually beneficial to the Harvard Medical School and CBIS, said Mr.
Dabney.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide
novel treatment approaches to a number of illnesses for which current treatments and understanding
remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and
currently, there are a growing number of peer-reviewed scientific publications that document the
underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts
in drug development, medicinal characterization, and clinical research to develop, produce, and
commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well
as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The
Company is proceeding with the research and development of its proprietary drugs as a part of this initial
focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such
as anticipate, seek, intend, believe, estimate, expect, project, plan, or similar phrases may be
deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Some or all of the events or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences include the future U.S. and global
economies, the impact of competition, and the Companys reliance on existing regulations regarding the
use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor
does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The
Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward looking statements.
Certain of the statements contained herein, which are not historical facts are forward looking statements
with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking
statements may be impacted, either positively or negatively, by various factors. Information concerning
potential factors that could affect the company are detailed from time to time in the companys reports
filed with the Securities and Exchange Commission.

CONTACT INFORMATION
Cannabis Science, Inc.
Investor Relations
Teresa Misenheimer
teresa@cannabisscience.com
Tel: 1-888-263-0832

Cannabis Science, Inc.

Mr. Raymond C. Dabney
Director, President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel:1-888-263-0832

Cannabis Science, Inc.

Dr. Allen Herman
Chief Medical Officer (CMO)
allen.herman@cannabisscience.com
Tel: 1-888-263-0832

This press release was distributed by the International Trade Council.

International Trade Council Member news does not necessarily represent the views of the Trade Council
nor the Council's employees. For more information on the International Trade council please visit
http://www.tradecouncil.org or drop by on Twitter at http:/www.twitter.com/inttradecouncil